Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada by Clarke, Brian et al.
AmpC β-lactamase, altered porins, or both are usually
responsible for cefoxitin resistance in Escherichia coli. We
examined the relative importance of each. We studied 18
strains of clinical isolates with reduced cefoxitin susceptibil-
ity and 10 initially-susceptible strains passaged through
cefoxitin-gradient plates. Of 18 wild-resistant strains, 9 had
identical promoter mutations (including creation of a con-
sensus 17-bp spacer) and related pulsed-field gel elec-
trophoresis patterns; the other 9 strains were unrelated.
Nine strains had attenuator mutations; two strains did not
express OmpC or OmpF. After serial passage, 8 of 10
strains developed cefoxitin resistance, none developed
promoter or attenuator mutations, 6 lost both the OmpC
and OmpF porin proteins, and 1 showed decreased pro-
duction of both. One strain had neither porin alteration or
increased AmpC production. Porin mutants may occur
more commonly and be less fit and less inclined to spread
or cause disease than strains with increased β-lactamase
expression.
T
he development of antibiotic resistance in Escherichia
coli has important clinical implications. E. coli is
among the most frequently isolated bacterium in a variety
of clinical settings. The development of resistance to older
agents such as ampicillin and trimethoprim-sulfamethoxa-
zole, as well as the emerging problem of fluoroquinolone
resistance, may substantially limit our antibiotic choices
(1,2).
Although cephamycin-resistant E. coli is relatively
uncommon, widespread use of β-lactam antiboties may
contribute to the development and spread of these strains.
In 1999, Sahm et al. reported that 0.16% of E. coli were
resistant to cephamycins (3). At a local level, unpublished
data from the Queen Elizabeth II Health Science Centre in
Halifax, Nova Scotia indicated that, of the 5,767 strains of
E. coli processed from urine samples, 0.4% were
cephamycin resistant. 
All strains of E. coli possess a gene that encodes an
AmpC β-lactamase. Usually, almost no β-lactamase is pro-
duced because the gene is preceded by a weak promoter
and a strong attenuator (4). Surveys of resistance mecha-
nisms in cephamycin-resistant strains have most often
identified promoter or attenuator mutations, which results
in an up-regulation of AmpC β-lactamase production
(5–7). Occasionally, cephamycin-resistant strains bear
mobilized  β-lactamases derived from bacteria such as
Citrobacter feundii (8). In addition, mutation or altered
expression of outer membrane proteins constituting porins
can also contribute to cephamycin resistance. To our
knowledge, no investigators have concurrently looked for
alterations in porins in addition to promoter-attenuator
mutations. Porin alterations might work together to pro-
duce a higher level of resistance. In addition, porin alter-
ations may protect E. coli and allow subsequent selection
for promoter and attenuator mutants.
We examined E. coli strains collected at our hospital to
determine the basis for resistance. In addition, we created
cephamycin-resistant strains of E. coli by serial passage on
cefoxitin-containing medium to determine which of these
two resistance mechanisms was predominant and if our
findings were representative of those seen in clinical iso-
lates. 
Materials and Methods
Bacterial Strains
We collected strains of E. coli from midstream urine
from inpatients and from patients in the community.
Eighteen strains with reduced susceptibility (MIC >8
mg/L) to cefoxitin were included in the analysis, which
represented all resistant strains collected during a 6-month
period in 2001. For the in vitro development of resistance,
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susceptible to β-lactam antibiotics. In both cases, we
excluded duplicate strains from the same patient. E. coli
isolates were identified with conventional biochemical
reactions. Organisms were identified by spot indole and β-
glucuronidase assays and confirmed by automated Vitek
by using GNI+ cards, and antibiotic susceptibilities were
performed by using GNS 606 cards (bioMerieux Canada
Inc., St. Laurent, Quebec). 
Analysis of Promoter and Attenuator Mutations
E. coli chromosomal DNA was isolated with a QIAmp
DNA Mini Kit (Qiagen Inc., Valencia, CA), according to
the manufacturer’s instructions. Using standard methods,
we performed polymerase chain reaction (PCR) with a pre-
viously published primer set and protocol which amplifies
the region of DNAincluding the –35 box of the AmpC pro-
moter and the 3′ end of the attenuator, producing a 271-bp
amplicon (5). Amplification was performed in a PTC-200
Peltier Thermal Cycler (MJ Research, Boston, MA). The
amplicons were resolved by 2% agarose gel electrophore-
sis and visualized after staining with ethidium bromide.
The amplicons were purified by using the QIAquick PCR
Purification Kit (Qiagen Inc.) and sequenced directly in
both directions by using the dideoxy chain termination
procedure of Sanger et al. on an ABI Prism automated
sequencer at York University Core Molecular Laboratory,
Toronto, Ontario, Canada.
Molecular Fingerprinting
Strains sharing similar promoter or attenuator muta-
tions were fingerprinted by pulsed field gel electrophoresis
(PFGE) by using a modification of the method of Gautom
(9). In brief, a standardized suspension of E. coli was pre-
pared from overnight cultures and treated with lysozyme
and proteinase K. Plugs were prepared in low-melt
agarose. Solidified plugs were deproteinated with sodium
lauryl sarcosine and proteinase K, and then washed repeat-
edly. Two millimeter slices of plug were digested with
Xbal at 37°C for 3 h in the recommended buffer. Plugs
were loaded onto a 1% agarose gel and resolved with a
CHEF-Mapper system (Bio-Rad Laboratories,
Mississauga, Ontario).
Outer Membrane Profiles
Bacteria were grown overnight in Luria-Burtani (LB)
broth with or without 4 mg/L of cefoxitin. To study Omp
expression, 30 mL of LB broth was injected with 300 µL
of a bacterial cell suspension from an overnight culture.
Cultures were incubated at 37°C in a shaking water bath at
250 rpm to an optical density at 600 nm of 1.0. Cell mem-
branes were disrupted with a sonicator for 2 min with 30-
sec cycles intermittent on ice. Cell debris was removed by
centrifugation at 10,000 g for 10 min at 4°C. Cytoplasmic
membrane proteins were differentially solubilized for 20
min at room temperature with 1.7% sodium-lauryl-sarcosi-
nate in 100 mM Tris, pH 8.0. The suspension was then cen-
trifuged at 100,000 g for 20 min at 4°C, and the pellet con-
taining the outer membrane proteins was resuspended in
100 µL sterile distilled water. Omp preparations were ana-
lyzed by urea-sodium dodecyl sulfate-polyacrylamide gel
electrophoresis at 30 mA in gels prepared with 11% acry-
lamide, 0.3% bisacrylamide, 8 M urea, and 0.1% SDS
using the discontinuous buffer system of Laemmli (10).
The gels were stained with Coomassie brilliant blue. The
positions of OmpC and OmpF on the Omp profiles were
ascertained by comparing the profiles of Omp preparations
from the E. coli reference strains MH760 (ompR472
OmpC- OmpF+) and MH1461 (envz11 OmpC+ OmpF-)
(11).
Development of Cefoxitin-resistant Strains
Cefoxitin-resistant mutants were obtained by serially
passaging the wild type strains on 9 cm x 9 cm2 gradient
plates containing a maximum of 32 mg/L cefoxitin in MH
agar, as previously described (12). Plates were incubated at
room temperature overnight before use to ensure proper
diffusion of the antibiotic. Streaked plates were incubated
overnight at 37°C and the colony that grew furthest up the
cefoxitin gradient was selected and replated on a fresh gra-
dient plate the following day. A total of 12 passages were
performed for each strain at a maximum concentration of
32 mg/L cefoxitin and an additional 15 passages at a max-
imum of 128 mg/L cefoxitin. Isoelectric focusing was per-
formed by using a modification of the method (13).
Results
Each of the 18 strains with reduced susceptibility to
cefoxitin was also resistant to ampicillin, cephalothin, and
amoxicillin/clavulanate acid. All were imipenem suscepti-
ble. Isoelectric focusing demonstrated chromosomal
AmpC in all strains; no other β-lactamases were identified.
A summary of promoter and attenuator mutations, as well
as alterations in outer membrane profiles, is shown in
Table 1 and Figures 1 and 2. Strains QE1–QE9 were iden-
tical or closely related by PFGE. Each strain had a 1-bp
insertion in the spacer region between the –35 and –10
boxes. This insertion created a consensus 17-bp spacer. In
addition to this mutation, these strains had additional
mutations at –73, +6, and +81. Strain QE7 also had a dele-
tion in the loop of the attenuator. None of these strains had
changes in their outer membrane protein profiles. 
The other nine strains (QE10–QE18) had different
PFGE patterns and came from diverse locations (different
hospitals and from both outpatients and inpatients). Strain
QE10 had a C to T mutation at –42 and a G to A at –18,
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T to A mutation at –32 that is necessary to create the
stronger –35 consensus sequence (QE14, 15). Strain QE14
also had the –11 C to T mutation that created the stronger
–10 consensus sequence (TACAAT). 
Only two strains had no promoter or attenuation loop
mutations and no abnormalities of the outer membrane
profile (QE16, QE17). Both of these strains had the C to T
mutation at position +58 of the attenuator. This mutation
would appear not to influence the development of the
attenuation loop. 
Of the 10 susceptible strains that were serially passaged
on gradient plates, 8 developed resistance to cefoxitin
(strains LD1–LD5, LD8–LD10). One of these strains had
mutations in the AmpC promoter or attenuator regions
(Table 2); this strain had two mutations, including a C to T
mutation in the left stem of the attenuator, which would
result in the transcription of a weak attenuation loop. Both
of the mutations were also seen in the initial clinical iso-
lates. This strain also had absent Omp C and Omp F. The
remaining cefoxitin-resistant strains either lacked Omp C
and Omp F (six strains) or had decreased amounts of
OmpC and OmpF (one strain). One strain had no muta-
tions in the promoter or attenuator and normal amounts of
Omp C and Omp F.
Discussion
The emergence of E. coli strains resistant to extended-
spectrum cephalosporins and cephamycins should be a
cause of concern to clinicians managing infections in both
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Table 1. Summary of promoter/attenuator mutations and porin changes in 18 clinical strains of Escherichia coli, arranged by pulsed-
field type
a 
MIC (µg/mL)  PFGE 
type  Strain  FOX  CAZ  CRO 
Patient 
Location  Promoter mutations  Attenuator mutations 
Outer membrane 
protein (Omp) profile 
A  QE1  16  <8  <8  HCC  T insertion (–13) to 
consensus spacer (17 bp) 
G to A, right stem; C to T, 
upstream of stem/loop 
No abnormalities 
A1  QE2  8  <8  <8  FD  T insertion (–13) to 
consensus spacer (17 bp) 
C to T, upstream of  
stem/loop 
No abnormalities 
A2  QE3  >32  <8  <8  Inpatient 
Ward A 
T insertion (–13) to 
consensus spacer (17 bp) 
C to T, upstream of stem/ 
loop; C deletion, right stem 
No abnormalities 
A2  QE4  16  <8  <8  FD  T insertion (–13) to 
consensus spacer (17 bp) 
C to T, upstream of 
stem/loop 
No abnormalities 
A3  QE5  16  <8  <8  ER  T insertion (–13) to 
consensus spacer (17 bp) 
C to T, upstream of 
stem/loop; C to T, left stem 
No abnormalities 
A4  QE6  >32  <8  <8  HCC  T insertion (–13) to 
consensus spacer (17 bp) 
C to T, upstream of 
stem/loop 
No abnormalities 
A5  QE7  >32  <8  <8  HCC  T insertion (–13) to 
consensus spacer (17 bp) 
C to T, upstream of 
stem/loop; ATG deletion in 
loop/right stem (+27 –29) 
No abnormalities 
A  QE8  16  <8  <8  FD  T insertion (–13) to 
consensus spacer (17 bp) 
C to T, upstream of stem/ 
loop; G to A, left stem 
No abnormalities 
A  QE9  >32  16  <8  Inpatient 
Ward B 
T insertion (–13) to 
consensus spacer (17 bp) 
C to T, upstream of stem/ 
loop; G to A, right stem 
No abnormalities 
B  QE10  >32  <8  <8  Inpatient 
Ward C 
C to T (–42); G to A  
(–18); C to T (–1) 
C to A, left stem; C to T, 
downstream of stem/loop 
No abnormalities 
C  QE11  >32  <8  <8  Inpatient 
Ward C 
G to A (–18); C to T (–1)  C to T, downstream of 
stem/loop 
No abnormalities 
D  QE12  >32  <8  <8  FD  G to A (–18); C to T (–1)  C to T, downstream 
stem/loop 
Omp F- 
E  QE13  >32  16  <8  FD  G to A in spacer (–28)  C to T, downstream 
stem/loop 
No abnormalities 
F  QE14  8  <8  <8  ER  T to A (–32), new –35 box; 
C to T (–11), new –10 box 
None  No abnormalities 
G  QE15  >32  16  <8  Inpatient 
Ward D 
T to A (-32), new –35 box  None  Omp C- 
H  QE16  >32  <8  <8  HCC  None  C to T, downstream 
stem/loop 
No abnormalities 
I  QE17  16  <8  <8  FD  None  C to T, downstream 
stem/loop 
No abnormalities 
J  QE18  >32  <8  <8  Inpatient 
Ward E 
None  C deletion, right stem 
(+31); C to T, downstream 
stem/loop 
No abnormalities 
aPFGE, pulsed-field gel electrophoresis; FOX, cefoxitin; CAZ, ceftazidime; CRO, ceftriaxone; HCC, Hants Community Clinic; FD, family doctor’s office; ER, 
emergency room. the community and institutional setting. Extended-spec-
trum cephalosporins and penicillins combined with β- lac-
tamase inhibitors are frequently used for both empirical
and definitive treatment of E. coli infections. Strains resist-
ant to cephamycins have emerged in recent years. Some of
these strains have become resistant by virtue of their
hyperproduction of chromosomally encoded AmpC β-lac-
tamases (5–7). Others have acquired plasmidic β-lacta-
mases; most often those derived from Citrobacter freundii
(8). 
In our survey of E. coli strains identified at our center,
we found that no strains were resistant as a result of
acquired-plasmid–mediated β-lactamases. These strains all
produced substantial amounts of AmpC β-lactamase with
the isoelectric point characteristic of the E. coli–derived
AmpC. The predominant reason for the hyperproduction
of AmpC appeared to be promoter mutations, attenuator
mutations, or both. 
Half of the strains appeared to be clonal in origin in that
they had the same promoter mutation and the same attenu-
ator mutations. Several of the strains had additional atten-
uator mutations; however, all of these strains had the same
pulsed-field pattern. None of the strains had alterations in
their OmpC or OmpF profiles. These strains came from
diverse locations within the Queen Elizabeth II Health
Sciences Centre complex and from other hospitals. Since
we had limited information on the movement of the infect-
ed patients within the healthcare system, we are unable to
define a common source.
The other nine strains had different pulsed-field pat-
terns. Two strains each had similar promoter mutations,
attenuator mutations, or both. Again, these strains came
from different locations within our center, the community,
and from referring hospitals. Two of these strains had
altered outer membrane profiles; one lacked OmpF, the
other OmpC. The promoter and attenuator mutations we
detected were very remarkably similar to those that had
been previously described in France, South Africa,
Sweden, and Toronto, Canada. In particular the –42, –31,
–18 mutations and spacer inserts have been consistently
reported. The –11 promoter mutation that we observed was
the second report of this mutation in the E. coliAmpC pro-
moter (14).
We were able to develop resistance in 8 of 10 strains in
vitro. Upon examination, seven of these strains had altered
outer membrane protein profiles; six lacked both OmpC
and OmpF, and one had decreased production of both of
these porin proteins. One strain did not have promoter or
attenuator mutations or alterations in the outer membrane
protein profile. Sequencing of the promoters and attenua-
tors indicated that only one had mutations that might have
affected the amount of β-lactamase produced. However,
this mutation was present in the wild strain as well.
We found that promoter abnormalities were common in
clinical strains but not in lab-generated cefoxitin-resistant
isolates. Increased resistance to antimicrobial agents has
been shown to be associated with loss of porins in E. coli
and other gram-negative organisms (15–19). The major
porin proteins of E. coli, OmpF and OmpC, are differen-
tially expressed at the transcriptional level by the two-
component regulatory proteins, EnvZ and OmpR. The sen-
sory protein, EnvZ, phosphorylates the transcriptional fac-
tor OmpR in response to environmental stress. The cellu-
lar level of the active form of OmpR, OmpR-phosphate
(OmpR-P), is responsible for the differential expression of
ompF and ompC (20). Therefore, the tension between the
kinase and phosphatase activities of EnvZ controls the
level of active OmpR-P in the cell. In the resistant strains
selected on gradient plates, we found that most lacked both
major outer membrane proteins in comparison to the
respective parent strain. The lack of outer membrane pro-
tein expression in these isolates could occur by several
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Figure 1. Sequences of Escherichia coli AmpC promoters showing
mutations detected in cephamycin-resistant strains. The consen-
sus sequence for E. coli K12 is shown in the last row. The promot-
er region is in boldface. The –35 and –10 (Pribnow box) hexamers
are underlined. The number of strains with these mutations is indi-
cated on the left.
Figure 2. Sequences of Escherichia coli AmpC attenuators that
were other than the consensus sequence for E. coli K12. The hair-
pin loop is in boldface, and the region of the dyad symmetry is
underlined. * indicates bp deletion. The number of strains with
these mutations is indicated on the left.mechanisms, including loss of kinase activity of EnvZ and
mutation of the transcription factor OmpR. 
Alternatively, resistance may arise because of
decreased pore diameter (21,22). The in vitro mutant with-
out quantitative changes in Omp C or OmpF or promoter
or attenuator mutations may have had this molecular
lesion. 
We postulate that, while porin deficient mutants are
more readily selected by antimicrobial pressure, they are
likely less fit. This finding is reflected by the fact that Omp
changes are easily created in the laboratory but not found
in clinical samples. As a result of their lower fitness, they
are more likely to be replaced by wild E. coli when antimi-
crobial pressure has been removed. On the other hand, the
widespread clonal dissemination of strains that hyperpro-
duce AmpC by virtue of promoter or attenuator mutations
suggests that they are much better able and more likely to
contribute to the spread of cephamycin resistance.
The ampC β-lactamase produced by E. coli hydrolyzes
penicillins, cephalosporins, and cephamycins. In doing so,
β-lactamase increases the MICs to third-generation
cephalosporins but, as our data suggest, seldom above the
breakpoint set by the National Committee for Clinical
Laboratory Standards (NCCLS). This situation is analo-
gous to that of many TEM- and SHB-derived β-lacta-
mases. Using third-generation cephalosporins or peni-
cillin/β-lactamase–inhibitor combinations to treat serious
infections caused by ampC up-regulated strains may be
more imprudent. Just as we would not be inclined to treat
an E. coli bearing an extended spectrum β-lactamase with
a ceftriaxone MIC of 2 mg/L with ceftriaxone, we would
not treat an ampC β-lactamase up-regulated E. coli strain
with a third-generation cephalosporin. To the best of our
knowledge, no publication has documented treatment fail-
ures in such circumstances, and no NCCLS guidelines
exist. Nevertheless, our practice is to report all of these
strains as resistant to third-generation cephalosporins and
to cautioning against their use.
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